Compare Incyte Corporation (INCY) vs Omnicom Group Inc. (OMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Omnicom Group Inc. — how do they compare? Incyte Corporation trades at $113.22 (market cap $22.85B), while Omnicom Group Inc. trades at $76.57 (market cap $20.97B). The key difference: Incyte Corporation and Omnicom Group Inc. are close in size by market cap, and Omnicom Group Inc. pays a 4.19% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Omnicom Group Inc. for 63 Days on average.
| INCY | OMC | |
|---|---|---|
Market Cap | $22.85B | $20.97B |
Volume | 1,927,029 | 2,092,899 |
Sector | Health | Media |
52-Week High | $129.93 | $88.94 |
52-Week Low | $83.80 | $67.27 |
Typical Hold Time | 33 Days | 63 Days |
Enterprise Value | $18.35B | $29.05B |
Dividend Yield | — | 4.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.61, up 0.15% on the day, with a mixed technical signal leaning bearish. The company reported strong 2025 results with revenue of $5.14B and net income of $1.29B, and recent earnings beats in Q1 and Q2 2026. Key developments include FDA approval for Atebrioz and a strategic focus on post-JAKAFI growth targeting $4B in non-JAKAFI sales by 2029.
The outlook is cautiously optimistic, supported by robust profitability and pipeline progress, but tempered by near-term earnings pressure and technical weakness. Risks include JAKAFI's patent expiration after 2029 and competitive threats. Analysts maintain a Buy consensus with a $132.43 price target, implying significant upside from current levels.
Omnicom Group (OMC) trades at $76.32, up 1.94% on the day, with a bullish technical signal but mixed earnings history. The company reported a net loss of $54.5 million in 2025 despite revenue growth to $17.27 billion, with a high P/E ratio of 206.62 but attractive P/S of 0.86. Recent news highlights leadership in digital marketing and $3.3 billion in new H1 2026 billings, supporting positive sentiment.
Outlook is cautiously optimistic given analyst consensus price target of $100.50 (32% upside) and strong institutional interest, but risks include ad market volatility, high debt, and thin net margins. The stock offers value through a 4.2% dividend yield and post-merger synergies, though investors should monitor earnings consistency and macroeconomic pressures on advertising spend.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →
